Abstract | BACKGROUND: Lymphocytes play a key role in asthma pathophysiology, secreting various cytokines involved in chronic inflammation. CHF6001 is a highly potent and selective phosphodiesterase type 4 ( PDE4) inhibitor designed for inhaled administration and has been shown to reduce the late asthmatic response. However, the effect of PDE4 inhibition on the different cytokines produced by lung lymphocytes from asthma patients has not been examined. METHODS: RESULTS: CONCLUSION:
|
Authors | Thomas Southworth, Manminder Kaur, Lynsey Hodgson, Fabrizio Facchinetti, Gino Villetti, Maurizio Civelli, Dave Singh |
Journal | Cytokine
(Cytokine)
Vol. 113
Pg. 68-73
(01 2019)
ISSN: 1096-0023 [Electronic] England |
PMID | 29934047
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2018 Elsevier Ltd. All rights reserved. |
Chemical References |
- tanimilast
- Anti-Inflammatory Agents
- Cytokines
- Phosphodiesterase 4 Inhibitors
- Receptors, Antigen, T-Cell
- Sulfonamides
- para-Aminobenzoates
- Cyclic Nucleotide Phosphodiesterases, Type 4
|
Topics |
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Asthma
(drug therapy, metabolism)
- Bronchoalveolar Lavage
(methods)
- Bronchoalveolar Lavage Fluid
- Cell Line
- Cyclic Nucleotide Phosphodiesterases, Type 4
(metabolism)
- Cytokines
(metabolism)
- Female
- Humans
- Lung
(drug effects, metabolism)
- Lymphocytes
(drug effects, metabolism)
- Male
- Middle Aged
- Phosphodiesterase 4 Inhibitors
(therapeutic use)
- Receptors, Antigen, T-Cell
(metabolism)
- Sulfonamides
(therapeutic use)
- para-Aminobenzoates
(therapeutic use)
|